JP2017524742A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524742A5 JP2017524742A5 JP2017528754A JP2017528754A JP2017524742A5 JP 2017524742 A5 JP2017524742 A5 JP 2017524742A5 JP 2017528754 A JP2017528754 A JP 2017528754A JP 2017528754 A JP2017528754 A JP 2017528754A JP 2017524742 A5 JP2017524742 A5 JP 2017524742A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- acid
- alkyl
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2014050556 | 2014-08-12 | ||
| NLPCT/NL2014/050556 | 2014-08-12 | ||
| PCT/NL2015/050555 WO2016024858A1 (en) | 2014-08-12 | 2015-07-29 | Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524742A JP2017524742A (ja) | 2017-08-31 |
| JP2017524742A5 true JP2017524742A5 (enExample) | 2018-09-06 |
| JP6670310B2 JP6670310B2 (ja) | 2020-03-18 |
Family
ID=51429345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017528754A Active JP6670310B2 (ja) | 2014-08-12 | 2015-07-29 | テトラヒドロキノリン誘導体の調製のための合成中間体の調製方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10112904B2 (enExample) |
| EP (2) | EP4083022A1 (enExample) |
| JP (1) | JP6670310B2 (enExample) |
| KR (1) | KR102572626B1 (enExample) |
| CN (1) | CN107108558B (enExample) |
| AR (1) | AR101509A1 (enExample) |
| AU (1) | AU2015302407B2 (enExample) |
| BR (1) | BR112017002873B1 (enExample) |
| CA (1) | CA2958040C (enExample) |
| CL (1) | CL2017000367A1 (enExample) |
| CY (1) | CY1125574T1 (enExample) |
| DK (1) | DK3180314T3 (enExample) |
| EA (1) | EA034357B1 (enExample) |
| ES (1) | ES2926775T3 (enExample) |
| HR (1) | HRP20221061T1 (enExample) |
| HU (1) | HUE059947T2 (enExample) |
| IL (1) | IL250525B (enExample) |
| LT (1) | LT3180314T (enExample) |
| MA (1) | MA40378B1 (enExample) |
| MX (1) | MX367908B (enExample) |
| PL (1) | PL3180314T3 (enExample) |
| PT (1) | PT3180314T (enExample) |
| RS (1) | RS63575B1 (enExample) |
| SG (1) | SG11201701077XA (enExample) |
| SI (1) | SI3180314T1 (enExample) |
| SM (1) | SMT202200385T1 (enExample) |
| TW (1) | TWI691490B (enExample) |
| WO (1) | WO2016024858A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2988112T3 (es) | 2021-03-05 | 2024-11-19 | Newamsterdam Pharma B V | Obicetrapib para el tratamiento de demencias |
| IL310115A (en) | 2021-07-26 | 2024-03-01 | Newamsterdam Pharma B V | Treatment of his hyporesponders |
| CA3242880A1 (en) | 2021-12-30 | 2023-07-06 | Newamsterdam Pharma B.V. | COMBINATION OF OBITECRAPIB AND SGLT2 INHIBITOR |
| US12006305B2 (en) | 2022-07-05 | 2024-06-11 | Newamsterdam Pharma B.V. | Salts of obicetrapib and processes for their manufacture and intermediates thereof |
| WO2024042061A1 (en) | 2022-08-22 | 2024-02-29 | Newamsterdam Pharma B.V. | Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions |
| EP4661865A1 (en) | 2023-02-07 | 2025-12-17 | NewAmsterdam Pharma B.V. | Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions |
| WO2025059594A1 (en) | 2023-09-15 | 2025-03-20 | Newamsterdam Pharma B.V. | METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH) |
| WO2025093129A1 (en) | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Treatment and prevention of age-related macular degeneration using a cetp inhibitor |
| WO2025093436A1 (en) | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Treatment and prevention of age-related macular degeneration using a cetp inhibitor |
| WO2025146262A1 (en) | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Obicetrapib for use in the treatment of hemoglobinopathies |
| WO2025146415A1 (en) | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Improvement in atherosclerotic plaque characteristics with obicetrapib |
| EP4746866A1 (en) | 2024-09-17 | 2026-05-27 | NewAmsterdam Pharma B.V. | Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (hefh) and/or atherosclerotic cardiovascular disease (ascvd) |
| WO2026062049A1 (en) | 2024-09-21 | 2026-03-26 | Newamsterdam Pharma B.V., | Obicetrapib for the treatment of dementias |
| WO2026063944A1 (en) | 2024-09-21 | 2026-03-26 | Newamsterdam Pharma B.V. | Obicetrapib for the treatment of dementias |
| WO2026087915A1 (en) | 2024-10-25 | 2026-04-30 | Newamsterdam Pharma B.V. | Treatment and prevention of sepsis or other dysregulated inflammatory responses using cetp inhibitor obicetrapib |
| WO2026115019A1 (en) | 2024-11-27 | 2026-06-04 | Newamsterdam Pharma B.V. | Enantioselective process for preparing tetrahydroquinoline derivatives |
| WO2026146129A1 (en) | 2025-01-02 | 2026-07-09 | Newamsterdam Pharma B.V. | Magnesium salts of obicetrapib |
| WO2026146132A1 (en) | 2025-01-02 | 2026-07-09 | Newamsterdam Pharma B.V. | Salts of obicetrapib |
| WO2026146133A1 (en) | 2025-01-02 | 2026-07-09 | Newamsterdam Pharma B.V. | Deuterated derivatives of obicetrapib |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| CA2445623A1 (en) * | 2001-04-30 | 2002-11-07 | Pfizer Products Inc. | Methods for preparing cetp inhibitors |
| UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| UY30244A1 (es) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
| CN101466679A (zh) * | 2006-03-30 | 2009-06-24 | 田边三菱制药株式会社 | 制备四氢喹啉衍生物的方法 |
-
2015
- 2015-07-29 CN CN201580046606.1A patent/CN107108558B/zh active Active
- 2015-07-29 ES ES15767345T patent/ES2926775T3/es active Active
- 2015-07-29 HR HRP20221061TT patent/HRP20221061T1/hr unknown
- 2015-07-29 SI SI201531874T patent/SI3180314T1/sl unknown
- 2015-07-29 HU HUE15767345A patent/HUE059947T2/hu unknown
- 2015-07-29 AU AU2015302407A patent/AU2015302407B2/en active Active
- 2015-07-29 EP EP22179712.9A patent/EP4083022A1/en active Pending
- 2015-07-29 SG SG11201701077XA patent/SG11201701077XA/en unknown
- 2015-07-29 CA CA2958040A patent/CA2958040C/en active Active
- 2015-07-29 BR BR112017002873-5A patent/BR112017002873B1/pt active IP Right Grant
- 2015-07-29 EP EP15767345.0A patent/EP3180314B1/en active Active
- 2015-07-29 JP JP2017528754A patent/JP6670310B2/ja active Active
- 2015-07-29 US US15/503,686 patent/US10112904B2/en active Active
- 2015-07-29 PL PL15767345.0T patent/PL3180314T3/pl unknown
- 2015-07-29 PT PT157673450T patent/PT3180314T/pt unknown
- 2015-07-29 WO PCT/NL2015/050555 patent/WO2016024858A1/en not_active Ceased
- 2015-07-29 DK DK15767345.0T patent/DK3180314T3/da active
- 2015-07-29 SM SM20220385T patent/SMT202200385T1/it unknown
- 2015-07-29 MA MA40378A patent/MA40378B1/fr unknown
- 2015-07-29 KR KR1020177006422A patent/KR102572626B1/ko active Active
- 2015-07-29 LT LTEPPCT/NL2015/050555T patent/LT3180314T/lt unknown
- 2015-07-29 RS RS20220810A patent/RS63575B1/sr unknown
- 2015-07-29 EA EA201790364A patent/EA034357B1/ru active IP Right Revival
- 2015-07-29 MX MX2017001930A patent/MX367908B/es active IP Right Grant
- 2015-08-10 TW TW104125888A patent/TWI691490B/zh active
- 2015-08-11 AR ARP150102597A patent/AR101509A1/es active IP Right Grant
-
2017
- 2017-02-09 IL IL250525A patent/IL250525B/en active IP Right Grant
- 2017-02-10 CL CL2017000367A patent/CL2017000367A1/es unknown
-
2022
- 2022-09-22 CY CY20221100631T patent/CY1125574T1/el unknown